Loading...

CNTA CENTESSA PHARMACEUTICALS PLC Investments/Divestments 8-K Filing

CNTS

CNT

CENTESSA PHARMACEUTICALS PLC

(CNTA)

2023 8-K

Show Summary

Summary

Product Expansion

Financial Statements

Financial Results

License Agreement

Investor Update

Financial Results

Positive Clinical Data

Financial Results

Annual General Meeting

Appointment of Chief Financ...

Financial Results Announcement

Underwriting Agreement

FDA Clears IND for Phase 1 ...

Financial Results Announcement

Investor Conferences

Investor Conferences

Data Presentation and Press...

Financial Results Announcement

Abstract Release

Financial Results and Prese...

Investor Conferences

Regulation FD Disclosure

Financial Results Announcement

Financial Results and Prese...

Sales Agreement with SVB Se...

FDA Clearance of IND Applic...

External Links:

Centessa Pharmaceuticals shared data from a Phase 2a study of SerpinPC at the ASH Annual Meeting and issued a press release with new data on the treatment of Hemophilia.

AI Assistant

CENTESSA PHARMACEUTICALS PLC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.